Placental transfer of indomethacin in the human pregnancy

https://doi.org/10.1016/0002-9378(90)90427-9Get rights and content

Little is known about the placental transfer of indomethacin in the human pregnancy. Twenty-six pregnant patients (gestational age, 29.4 ± 0.5 weeks) were given a 50 mg oral dose of indomethacin 6.08 ± 0.07 hours before 42 cordocenteses undertaken for standard indications. Maternal serum, fetal serum, and amniotic fluid levels were measured at the time of each procedure. Maternal indomethacin levels were not significantly different from corresponding fetal levels (218 ± 21 vs 219 ± 13 ng/ml). The maternal/fetal serum ratio (0.97 ± 0.07) was not found to vary with gestational age (R = -0.07, p = 0.66). Fetal serum levels were significantly higher than corresponding amniotic fluid levels (219 ± 16 vs. 21 ± 2 ng/ml; p < 0.001). The fetal/amniotic fluid ratio (10.0 ± 1.2) did not vary with gestational age (R = 0.33, p = 0.11). Indomethacin crosses the human placenta easily throughout gestation; only small amounts of the unchanged drug are found in the amniotic fluid.

References (14)

There are more references available in the full text version of this article.

Cited by (95)

  • Pharmacokinetics in pregnancy

    2022, Reproductive and Developmental Toxicology
  • Antenatal Risk Factors Associated with Spontaneous Intestinal Perforation in Preterm Infants Receiving Postnatal Indomethacin

    2021, Journal of Pediatrics
    Citation Excerpt :

    Associations between postnatal prophylactic indomethacin and SIP remain controversial.20-22 There is biologic plausibility for antenatal indomethacin as a risk factor for postnatal SIP reflecting ready passage across the placenta23 and reductions in regional blood flow to the intestine, kidneys, and cerebrum.24,25 There are limited data on associations of antenatal indomethacin exposure with SIP because the latter was not analyzed in meta-analyses.26,27

  • Preventing preterm birth: New approaches to labour therapeutics using Nanoparticles

    2018, Best Practice and Research: Clinical Obstetrics and Gynaecology
    Citation Excerpt :

    This is because most therapeutics lack specificity and being small molecules they can cross the placenta to enter the foetus, where they can affect foetal development [12]. A prominent example is indomethacin, which upon crossing the placenta and entering the foetus [23] can cause necrotising enterocolitis [24] and intraventricular haemorrhage [25] and affect closure of the ductus arteriosus [26–28]. Despite prostaglandin synthesis inhibitors, such as indomethacin, having one of the highest probabilities of delaying labour and improving neonatal and maternal outcomes [2], the associated side effects are sufficient to negate their use.

View all citing articles on Scopus
View full text